Rare Disease Medicines Access Program (RDMAP)

What are the objectives of the program?

To provide access to free Enzyme Replacement Therapy (ERT) infusion initially for patients with Type 1 and 3Gaucher’s Disease and to ensure compliance to treatment and management protocol of the identified patient beneficiaries through the Patient Navigation Program.

What is Rare Disease Medicines Access Program (RDMAP)?

DOH is embarking on a program that will provide health care access to patients with rare disease through the Rare Disease Medicines Access Program. Filipino patients born with rare diseases are “orphaned” by society. They suffer from social abandonment because of lack of existing network of support to aid them. Medical help is elusive under the conditions of the country’s health priority. The nature of their illness is hardly known due to lack of information and only a few medical professionals in the country are aware of these disorders and know how to diagnose and address these conditions.

Who are the target beneficiaries of the Rare Disease Medicines Access Program (RDMAP)?

Initial target beneficiaries are children with Types 1 and 3 Gaucher Disease referred by the (Institute of Human Genetics) IHG who qualify based on a standard screening process. Patients shall undergo treatment and management and have their regular Enzyme Replacement Therapy infusion.